Loading...
EHA congress 20242025-01-28T15:55:37+01:00

EHA 2024

Lecture Board: Othman Al-Sawaf, MD; Tycel Philipps, MD; John Seymour, MD; Constantine Tam, MD; Umberto Vitolo, MD; Talha Munir, MD
Medical Writer: Judith Moser, MD
Publishing Editor: Anna Fenzl, PhD

DOWNLOADS

All downloads from EHA 2024

EHA2024_Memo Congress report

Slide Kit

Full report (english)

EXPERT VIDEOS

All video interviews from EHA 2024

Chan Cheah discusses key aspects of a disease-centered treatment approach for relapsed/refractory CLL, explains how B-cell degraders, compared to BTK inhibitors, can improve management of B cell malignancies, and highlights notable results for the BTK degrader BGB-16673 in relapsed or refractory indolent non-Hodgkin lymphoma.

Umberto Vitolo discusses emerging T-cell–engaging agents for B-cell lymphomas and their potential impact. He highlights the effectiveness of bispecific antibody therapy in later-line follicular lymphoma and shares insights from the EPCORE NHL-1 study, highlighting key safety and tolerability precautions for patients receiving the bispecific antibody epcoritamab.

Consuelo Bertossi explains how TP53 mutations affect the prognosis of CLL patients and their impact on treatment decisions. She also discusses the significance of co-occurring genetic alterations and highlights the influence of TP53 mutations on the efficacy of different treatment approaches in CLL, ahead of her presentation at this year’s EHA congress.

Nitin Jain elucidates the promising outcomes of the time-limited triplet therapy with pirtobrutinib, venetoclax, and obinutuzumab in first-line CLL treatment and addresses future challenges in clinical implementation. He shares recent advances in the development of more potent BTK inhibitors and depicts his personal highlights from this year’s EHA congress.

Clemens Wendtner provides insights on treatment selection in CLL, emphasizing key principles for first-line therapy and summarizes the recent GAIA/CLL13 data comparing venetoclax combinations with chemoimmunotherapy in fit untreated patients. Additionally, he discusses factors guiding treatment choices in relapsed/refractory CLL and highlights the benefits of BTK inhibitors in indolent lymphomas.

Talha Munir overviews the performance of next-generation BTK inhibitors like zanubrutinib in treating CLL, highlighting their efficacy and safety compared to older BTK inhibitors while further explaining the concept of matching-adjusted indirect comparison and its importance in future research. Lastly, he discusses how next-generation BTK inhibitors impact quality of life and their economic implications in B-cell malignancies.

Go to Top